ESCRS - FPS09.10 - Visual Performance, Spectacle Independence, Patient Satisfaction And Visual Distrubances Of Wavefront Shaping Presbyopia Correcting Iol Implanted With Mini-Monovision.

Visual Performance, Spectacle Independence, Patient Satisfaction And Visual Distrubances Of Wavefront Shaping Presbyopia Correcting Iol Implanted With Mini-Monovision.

Published 2022 - 40th Congress of the ESCRS

Reference: FPS09.10 | Type: Free paper | DOI: 10.82333/jr5k-d568

Authors: James Ball* 1 , Gurpal Jutla 2 , Caridad Peres-Vivez 3

1Custom Vision Clinic,Wetherby,United Kingdom;Ophthalmology,Leeds Teaching Hospitals, NHS Trust,Leeds,United Kingdom, 2Custom Vision Clinic,Wetherby,United Kingdom, 3Alcon LLC.,Fort Worth, Tx,United States

Purpose

To report real-world visual outcomes and PROMS in subjects with mini-monovision and emmetropia after bilateral implantation of AcrySof IQ Vivity presbyopia-correcting IOLs (models DFT015 and DFTX15-Toric).

Setting

Multicenter, ambispective registry study conducted in Europe, the UK, Australia and New Zealand evaluating the performance of bilaterally implanted AcrySof IQ Vivity and AcrySof IQ Vivity Toric IOL in a real world setting through routine clinical practice.

Methods

Mini-monovision target group was defined through MRSE at study entry visit when at least one eye with MRSE less than or equal to -0.50 D and the absolute difference in MRSE between two eyes were greater than or equal to 0.50 D. Emmetropia target group were all subjects who did not fall in mini-monovision target group definition. After approximately 3 months follow-up per local clinical practice standards, binocular distance, intermediate (66 cm), and near (40 cm) uncorrected and corrected visual acuities (UCDVA/BCDVA, UCIVA/DCIVA and UCNVA/DCNVA), as well as satisfaction, spectacle independence and visual disturbances were evaluated.

Results

At the study entry visit, 162 subjects were in the mini-monovision group and 527 subjects in the emmetropia group. Binocular mean logMAR (SD) UCDVA, UCIVA and UCNVA were 0.035 (0.098) ), 0.075 (0.114) and 0.204 (0.145) for the mini-monovision group and 0.007 (0.104), 0.087 (0.127) and 0.254 (0.157) for the emmetropia group, respectively. Patients reported never/rarely using spectacles at near, intermediate and distance by 71.4%, 91.9% and 87.7% for the mini-monovision and 54.3%, 90.0% and 93.9% for the emmetropia group, respectively. More than 90% of subjects reported no halos, glare and starbursts in both groups, and 88.9% and 91.9% were satisfied with their sight for the mini-monovision and emmetropia groups, respectively.

Conclusions

This real-world assessment of subjects with mini-monovision and emmetropia target after bilateral implantation of AcrySof IQ Vivity and/or AcrySof IQ Vivity Toric suggest an improvement at near visual acuity and spectacle independence with mini-monovision target group compared to emmetropia group while maintaining visual performance at distance and intermediate, as well as low level of visual disturbances.